Clinical significance of SH2B3 (LNK) expression in paediatric B-cell precursor acute lymphoblastic leukaemia

Br J Haematol. 2018 Oct;183(2):327-330. doi: 10.1111/bjh.14981. Epub 2017 Oct 29.

Mio Yano^{1

2

3}, Toshihiko Imamura^{1

3}, Daisuke Asai⁴, Takao Deguchi⁵, Yoshiko Hashii⁶, Mikiya Endo⁷, Atsushi Sato⁸, Hirohide Kawasaki⁹, Yoshiyuki Kosaka¹⁰, Koji Kato¹¹, Hiroki Hori⁵, Keiko Yumura-Yagi¹², Junichi Hara¹³, Megumi Oda¹⁴, Keizo Horibe³

¹ Department of Paediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
² Department of Paediatrics, Kyoto City Hospital, Kyoto, Japan.
³ Clinical Research Centre, National Hospital Organization Nagoya Medical Centre, Nagoya, Japan.
⁴ Department of Paediatrics, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
⁵ Department of Paediatrics, Mie University, Tsu, Japan.
⁶ Department of Paediatrics, Osaka University, Osaka, Japan.
⁷ Department of Paediatrics, Iwate Medical University, Iwate, Japan.
⁸ Department of Haematology and Oncology, Miyagi Children's Hospital, Sendai, Japan.
⁹ Department of Paediatrics, Kansai Medical University, Hirakata, Japan.
¹⁰ Department of Haematology and Oncology, Hyogo Prefectural Children's Hospital, Kobe, Japan.
¹¹ Department of Haematology Oncology, Children's Medical Centre, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
¹² Yumura Clinic, Osaka, Japan.
¹³ Department of Paediatric Haematology/Oncology, Osaka City General Hospital, Osaka, Japan.
¹⁴ Department of Paediatrics, Okayama University, Okayama, Japan.

No abstract available

Keywords: SH2B3 (LNK); biomarker; paediatric B-ALL; prognostic factor.

Publication types